Poster presentations:
- Construction of External Control Arms (ECA) in Relapsed and Refractory Multiple Myeloma (RRMM)
- Using Bayesian Methodology to Minimize Control Recruitment in Trials of Relapsed and Refractory (RR) Multiple Myeloma (MM) Through Incorporation of Prior Control Response Information Borrowed From Real World Evidence
- Characterisation of Demography and Comorbidity in Newly Diagnosed Multiple Myeloma Patients in the UK
- The impact of COVID 19 on treatment of patients with ovarian cancer in England
- Characterisation Of Time-To-Treatment-Discontinuation (TTTD) As A Proxy for Progression-Free Survival (PFS) In Real-World-Evidence (RWE) Based Analyses Of Relapsed-Refractory Multiple Myeloma (RRMM)
- Treatment Pathways and Outcomes of Advanced Ovarian Cancer Patients Who Are Underrepresented in Trials